IceCure Medical Ltd. (NASDAQ:ICCM - Get Free Report)'s stock price traded down 8.9% during trading on Monday . The stock traded as low as $0.91 and last traded at $0.92. 1,994,296 shares were traded during mid-day trading, a decline of 22% from the average session volume of 2,549,969 shares. The stock had previously closed at $1.01.
Wall Street Analysts Forecast Growth
ICCM has been the topic of several recent analyst reports. Wall Street Zen downgraded IceCure Medical from a "hold" rating to a "sell" rating in a research note on Saturday, July 12th. HC Wainwright reiterated a "buy" rating and set a $2.50 price objective on shares of IceCure Medical in a research note on Thursday, May 29th.
View Our Latest Stock Report on ICCM
IceCure Medical Stock Down 4.5%
The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.48 and a current ratio of 1.89. The company has a market cap of $49.83 million, a price-to-earnings ratio of -3.04 and a beta of 0.32. The business's 50 day simple moving average is $1.00 and its 200-day simple moving average is $1.14.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last announced its quarterly earnings data on Wednesday, May 28th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The business had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.75 million. IceCure Medical had a negative net margin of 467.37% and a negative return on equity of 182.26%. During the same quarter last year, the company posted ($0.08) earnings per share. Sell-side analysts expect that IceCure Medical Ltd. will post -0.28 earnings per share for the current year.
Hedge Funds Weigh In On IceCure Medical
A hedge fund recently raised its stake in IceCure Medical stock. XTX Topco Ltd grew its holdings in IceCure Medical Ltd. (NASDAQ:ICCM - Free Report) by 123.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 58,866 shares of the company's stock after purchasing an additional 32,555 shares during the quarter. XTX Topco Ltd owned approximately 0.11% of IceCure Medical worth $65,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.62% of the company's stock.
About IceCure Medical
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
See Also
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access